Clin2Atlas
AtlasCancersNeoplasms

Mesothelioma

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020252004 — Pemetrexed approved (FDA)2011 — Ipilimumab approved (FDA)2015 — Nivolumab approved (FDA)
2004: Drug approval — Pemetrexed approved (FDA). 2011: Drug approval — Ipilimumab approved (FDA). 2015: Drug approval — Nivolumab approved (FDA)

What's being tested now

2005: 1 trials started2008: 1 trials started2009: 1 trials started2010: 1 trials started2011: 1 trials started2013: 3 trials started2015: 2 trials started2016: 1 trials started2017: 2 trials started2018: 3 trials started2019: 6 trials started2020: 3 trials started2021: 10 trials started2022: 6 trials started2023: 21 trials started2024: 23 trials started2025: 16 trials started2026: 15 trials started20102020202623

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 106 active Malignant Pleural Mesothelioma trials on Clin2 →

Related

Lip and oral cavity cancerNasopharynx cancerOther pharynx cancerEsophageal cancerStomach cancerColon and rectum cancerGallbladder and biliary tract cancerPancreatic cancerLarynx cancerTracheal, bronchus, and lung cancerMalignant skin melanomaSoft tissue and other extraosseous sarcomas

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.